Milana Flavio, Polidoro Michela Anna, Famularo Simone, Lleo Ana, Boldorini Renzo, Donadon Matteo, Torzilli Guido
Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy.
Department of Hepatobiliary and General Surgery, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy.
Cancers (Basel). 2023 Jan 13;15(2):508. doi: 10.3390/cancers15020508.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and both liver resection and liver transplantation are considered potentially curative options. However, high recurrence rates affect the prognosis depending both on the primary HCC pathology characteristics or on the type and time of the relapse. While great attention has been usually posted on treatment algorithms for the first HCC, treatment algorithms for recurrent HCC (rHCC) are lacking. In these cases, surgery still represents a curative option with both redo hepatectomy and/or salvage liver transplantation, which are considered valid treatments in selected patients. In the current era of personalised medicine with promises of new systemic-targeted immuno-chemotherapies, we wished to perform a narrative review of the literature on the role of surgical strategies for rHCC.
肝细胞癌(HCC)是最常见的原发性肝癌,肝切除和肝移植均被视为潜在的治愈性选择。然而,高复发率会影响预后,这既取决于原发性HCC的病理特征,也取决于复发的类型和时间。虽然通常对首次发生的HCC的治疗方案给予了极大关注,但复发性HCC(rHCC)的治疗方案却很缺乏。在这些情况下,手术仍然是一种治愈性选择,包括再次肝切除和/或挽救性肝移植,这在选定的患者中被认为是有效的治疗方法。在当前这个有希望采用新的全身靶向免疫化疗的个性化医疗时代,我们希望对关于rHCC手术策略作用的文献进行叙述性综述。